The estimated Net Worth of Stephen J Carriere is at least $8 dollars as of 19 January 2023. Mr Carriere owns over 354 units of Evelo Biosciences Inc stock worth over $8 and over the last 21 years he sold EVLO stock worth over $0.
Mr has made over 1 trades of the Evelo Biosciences Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 354 units of EVLO stock worth $8 on 19 January 2023.
The largest trade he's ever made was exercising 354 units of Evelo Biosciences Inc stock on 19 January 2023 worth over $8. On average, Mr trades about 22 units every 0 days since 2003. As of 19 January 2023 he still owns at least 354 units of Evelo Biosciences Inc stock.
You can see the complete history of Mr Carriere stock trades at the bottom of the page.
Stephen J. Carriere is the VP & Chief Accounting Officer at Evelo Biosciences Inc.
Mr Carriere is 66, he's been the VP & Chief Accounting Officer of Evelo Biosciences Inc since . There are no older and 15 younger executives at Evelo Biosciences Inc.
Stephen's mailing address filed with the SEC is C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 7 years, insiders at Evelo Biosciences Inc have traded over $41,656 worth of Evelo Biosciences Inc stock and bought 38,579,214 units worth $81,620,674 . The most active insiders traders include Ventures Fund Iv General Pa..., Noubar Afeyan und Ventures Fund Iv General Pa.... On average, Evelo Biosciences Inc executives and independent directors trade stock every 45 days with the average trade being worth of $19,676. The most recent stock trade was executed by Mark Bodmer on 7 November 2023, trading 6,625 units of EVLO stock currently worth $149.
evelo biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. these new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. by finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, evelo can improve the speed, cost and success of drug discovery and development. evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. evelo biosciences was conceived and created within venturelabs®, flag
Evelo Biosciences Inc executives and other stock owners filed with the SEC include: